EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.

D2C7-ATC therapy is linked to prolonged survival in a subset of patients with IDHwt recurrent glioblastoma, with a median overall survival of 17.38 months in certain cases.

• Why it matters: Glioblastoma has limited treatment options and poor prognosis, highlighting the need for targeted therapies that can improve survival outcomes and identify responsive patient subgroups.
• What they did: A phase 1 trial evaluated a single infusion of D2C7-ATC in 81 patients with recurrent malignant glioma, assessing toxicity, dose, overall survival, and biomarkers, including 72 with IDHwt rGBM.
• The result: D2C7-ATC was generally well tolerated, with a median overall survival of 7.9 months overall, but patients with specific biomarkers, such as tumor D2C7 antibody reactivity and low IL-8, showed notably longer survival, suggesting immune activation may enhance treatment benefit.